Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia
Cutaneous flushing with niacin varies between individuals and is substantially reduced by concomitant laropiprant. We investigated associations between baseline phenotypes and selected genotypes and flushing symptoms with niacin/laropiprant combination. Flushing symptoms were quantified in 196 Chinese dyslipidaemic patients treated with niacin/laropiprant, and associations with phenotypes and selected polymorphisms were analyzed. Moderate or severe flushing was associated with lower body mass index and the rs2279238 polymorphism in the LXRα on multivariate regression analysis and these factors accounted for 18.9% of the total variance. Lower body mass index and the LXRα polymorphism appear to be associated with flushing symptoms with niacin/laropiprant. Whether these findings can be applicable to other niacin formulations without laropiprant needs to be verified..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 16(2015), 12, Seite 1387-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Miao [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.2217/pgs.15.79 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1960943170 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1960943170 | ||
| 003 | DE-627 | ||
| 005 | 20230513214249.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs.15.79 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1960943170 | ||
| 035 | |a (DE-599)GBVOLC1960943170 | ||
| 035 | |a (PRQ)c1916-2351fd15a41b6ef6338fc9f736b4792ec548a01aaeccb159c2424737e3be11a50 | ||
| 035 | |a (KEY)0406126820150000016001201387pharmacogeneticsofcutaneousflushingresponsetoniaci | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Hu, Miao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Cutaneous flushing with niacin varies between individuals and is substantially reduced by concomitant laropiprant. We investigated associations between baseline phenotypes and selected genotypes and flushing symptoms with niacin/laropiprant combination. Flushing symptoms were quantified in 196 Chinese dyslipidaemic patients treated with niacin/laropiprant, and associations with phenotypes and selected polymorphisms were analyzed. Moderate or severe flushing was associated with lower body mass index and the rs2279238 polymorphism in the LXRα on multivariate regression analysis and these factors accounted for 18.9% of the total variance. Lower body mass index and the LXRα polymorphism appear to be associated with flushing symptoms with niacin/laropiprant. Whether these findings can be applicable to other niacin formulations without laropiprant needs to be verified. | ||
| 650 | 4 | |a Body mass index | |
| 650 | 4 | |a Antilipemic agents | |
| 650 | 4 | |a Pharmacogenetics | |
| 700 | 1 | |a Yang, Ya-Ling |4 oth | |
| 700 | 1 | |a Chan, Paul |4 oth | |
| 700 | 1 | |a Tomlinson, Brian |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d London : Future Medicine, 2000 |g 16(2015), 12, Seite 1387-11 |w (DE-627)320595625 |w (DE-600)2019513-8 |w (DE-576)364344261 |x 1462-2416 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2015 |g number:12 |g pages:1387-11 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.2217/pgs.15.79 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26226939 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1711662895 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 16 |j 2015 |e 12 |h 1387-11 | ||